| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Outlook Therapeutics Inc. | ONS-5010 -(NORSE 4) | Branch retinal vein occlusion (BRVO) | Phase 3 | Trial Planned | intravitreal injection | Opthalmic |
| Outlook Therapeutics Inc. | ONS-5010 - (NORSE 5 and 6) | Diabetic macular edema (DME) | Phase 3 | Trial Planned | Intravitreal | Opthalmic |
| Outlook Therapeutics Inc. | ONS-5010 - (NORSE 5 and 6) | Diabetic macular edema (DME) | Phase 3 | Trial Planned | Intravitreal | Opthalmic |
| Outlook Therapeutics Inc. | ONS-5010 -(NORSE 4) | Branch retinal vein occlusion (BRVO) | Phase 3 | Trial Planned | intravitreal injection | Opthalmic |
| Ovid Therapeutics Inc. | OV101 - NEPTUNE | Adolescents with Angelman syndrome | Phase 3 | Trial Completed | Oral | Genetic Disorder |
| Ovid Therapeutics Inc. | Soticlestat (TAK-935/OV935)- (Skyline) | Dravet Syndrome / Lennox-Gastaut Syndrome | Phase 3 | Data Released | Oral | Neurology |
| Ovid Therapeutics Inc. | OV101 - NEPTUNE | Adolescents with Angelman syndrome | Phase 3 | Trial Completed | Oral | Genetic Disorder |
| Ovid Therapeutics Inc. | OV888/GV101 | Cerebral cavernous malformations (CCM) | Phase 2 | Clinical Pause | intravenous | Neurology |